Bruker Corporation (NASDAQ: BRKR) has recently received a number of price target changes and ratings updates:

  • 11/10/2017 – Bruker Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Bruker exited the third quarter on a solid note with better-than-expected earnings and revenue performance. Scientific Instruments segment performed well where growth was driven by strong results within NANO and CALID groups. The company also raised 2017 guidance, which is indicative of brighter prospects. Moving on, the company’s strategic acquisition activity has been encouraging. In this context, the company recently announced the completion of acquisition of Germany-based MERLIN whose products can complement Bruker’s MALDI Biotyper platform. Following its promising third quarter 2017 performance, Bruker has been observed to trade above the broader industry over the past three months. On the flip side, currency fluctuations, competitive landscape and macroeconomic headwinds continue to pose challenges for the company.”
  • 11/8/2017 – Bruker Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $37.00 price target on the stock. According to Zacks, “Bruker exited the third quarter on a solid note with better-than-expected earnings and revenue performance. Scientific Instruments segment performed well where growth was driven by strong results within NANO and CALID groups. The company also raised 2017 guidance, which is indicative of brighter prospects. Moving on, the company’s strategic acquisition activity has been encouraging. In this context, the company recently announced the completion of acquisition of Germany-based MERLIN whose products can complement Bruker’s MALDI Biotyper platform. Following its promising third quarter 2017 performance, Bruker has been observed to trade above the broader industry over the past three months. On the flip side, currency fluctuations, competitive landscape and macroeconomic headwinds continue to pose challenges for the company.”
  • 11/3/2017 – Bruker Corporation was upgraded by analysts at Bank of America Corporation from an “underperform” rating to a “neutral” rating. They now have a $34.00 price target on the stock.
  • 11/3/2017 – Bruker Corporation had its “hold” rating reaffirmed by analysts at Cowen and Company. They now have a $29.00 price target on the stock.
  • 11/3/2017 – Bruker Corporation was upgraded by analysts at J P Morgan Chase & Co from an “underweight” rating to a “neutral” rating. They now have a $28.00 price target on the stock.
  • 11/3/2017 – Bruker Corporation had its price target raised by analysts at Citigroup Inc. from $29.00 to $34.00. They now have a “neutral” rating on the stock.
  • 9/26/2017 – Bruker Corporation had its “sell” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $24.00 price target on the stock.

Shares of Bruker Corporation (NASDAQ BRKR) traded down $0.58 during trading hours on Monday, hitting $31.83. 944,200 shares of the stock were exchanged, compared to its average volume of 632,677. Bruker Corporation has a 1-year low of $21.03 and a 1-year high of $35.16. The company has a quick ratio of 1.60, a current ratio of 2.60 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $4,951.56, a PE ratio of 27.20, a price-to-earnings-growth ratio of 2.69 and a beta of 1.05.

Bruker Corporation (NASDAQ:BRKR) last announced its earnings results on Thursday, November 2nd. The medical research company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.02. Bruker Corporation had a net margin of 8.85% and a return on equity of 25.83%. The business had revenue of $435.60 million during the quarter, compared to analysts’ expectations of $415.45 million. During the same period in the prior year, the company earned $0.32 earnings per share. The business’s revenue was up 10.6% compared to the same quarter last year. equities research analysts forecast that Bruker Corporation will post 1.19 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 22nd. Stockholders of record on Monday, December 4th will be paid a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.50%. Bruker Corporation’s dividend payout ratio (DPR) is 17.02%.

In other news, VP Mark Munch sold 21,061 shares of the business’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total transaction of $631,198.17. Following the transaction, the vice president now directly owns 60,524 shares in the company, valued at $1,813,904.28. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 35.20% of the company’s stock.

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.